Personalized cancer vaccine shows promise in initial trial

Researchers at the Icahn School of Medicine have tested a new personalized cancer vaccine, PGV001, in a small phase 1 trial. This vaccine uses multiple peptides to help the immune system recognize and attack cancer cells. The trial involved 13 patients with various cancers who were at high risk of recurrence. Early results showed no serious side effects, with six patients surviving five years, and three of them being tumor-free. Mount Sinai plans to conduct larger studies on PGV001 and explore its use with other cancer treatments. Three additional trials are already in the works for different types of cancer.